ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks. The company's products in development include Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus disease; and non-toxigenic strains of C. difficile, which is in preclinical stage for the treatment and prevention of CDI. It licensed the third product development candidate, an intranasal formulation of pleconaril, to Schering-Plough for the treatment of picornavirus infections in the U.S. and Canada. It sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. The company has strategic relationships with Eli Lilly and Company, GlaxoSmithKline, Schering-Plough Corporation, and Sanofi-Aventis.

Vivalis SA was founded in 1999 and is headquartered in Saint-Herblain, France. Vivalis SA, a biopharmaceutical company, develops and sells cell-based solutions to the pharmaceutical industry for the manufacture of viral vaccines and therapeutic proteins. Its proprietary technologies include EB66 cell line platform, which is derived from duck embryonic stem cells that presents industrial and regulatory characteristics to replace the eggs in the production of vaccines and to produce antibodies with enhanced antibody dependent cell cytotoxicity activity; and the 3D-SCREEN molecular screening platform that is used to identify and develop molecules for the purpose of blocking the action of proteins involved in major viral pathologies. The company also develops drugs for the prevention and treatment of viral diseases, notably for the treatment of hepatitis C.

Viventia Biotechnologies Inc., a biopharmaceutical company, offers a portfolio of novel antibody-based drugs for the treatment of cancer. Its lead product, Proxinium is used for the treatment of head and neck cancer. The company also offers Vicinium, a product for the treatment of bladder cancer; and VB6-845, a product for the treatment of solid tumors. Viventia specializes in the discovery and development of a portfolio of monoclonal antibodies for the treatment of common cancers. It also has a location in Winnipeg, Canada. The company was formerly known as Novopharm Biotech, Inc. and changed its name to Viventia Biotech, Inc. in 2000. The company was is headquartered in Mississauga, Canada. As of December 28, 2005, Viventia Biotechnologies Inc. operates as a subsidiary of Dan Family Holdings, Ltd.

VIVUS, Inc. company was founded in 1991 and is headquartered in Mountain View, California. VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in Phase III clinical trials for obesity and in Phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which the two of the Phase III studies are in process and one Phase III study has been completed; Qnexa for treating diabetes, for which a one-year Phase II study has been completed; Avanafil, is being developed for the treatment of erectile dysfunction; for which Phase III studies are in process, and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a Phase II study has been completed.

Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

Since its inception in 1740, Whatman knows what it takes to separate the wheat from the chaff. Whatman company makes filters, membranes, and specialty products for applications in the analytical, health care, and bioscience markets in some 70 countries. Whatman company's products can be found in medical devices and diagnostic testing kits. Whatman has also developed technology for the isolation, transportation, storage, and purification of DNA for gathering genetic information. Whatman makes other products such as blotting papers, syringe filters, and chromatography products. Whatman company was acquired by GE Healthcare in 2008.

The Whitehead Institute for Biomedical Research blazes new trails in bioscience. The organization, funded by both the public and private sectors, investigates such diseases as Parkinson's and cancer and dives into the depths of biology, genomics, and genetics to gain new understanding about disease and health. The Whitehead Institute contributed to the international effort to map the human genome, and is actively researching stem cells. Other achievements include discovering a system for multiplying adult stem cells and creating the first genetically defined human cancer cell. The institute was founded in 1982 by philanthropist Edwin "Jack" Whitehead and draws researchers from MIT.

Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

Xencor, Inc. company tailors proteins, not pants. Xencor is developing therapeutics for cancer, inflammatory ailments, and autoimmune diseases. The company engineers antibodies using its Protein Design Automation (PDA) technology, which allows for the specific targeting of diseased cells. Its drug candidates aim to treat cancerous conditions such as Hodgkin's lymphoma, T-cell lymphomas, and B-cell malignancies, as well as other autoimmune diseases. Research partners include Centocor, Genentech, Eli Lilly, and Human Geonome Sciences.

XenoPort, Inc. company was founded in 1999 and is based in Santa Clara, California. XenoPort, Inc., a biopharmaceutical company, focuses on developing internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. Its portfolio of product candidates includes XP13512, which is a transported prodrug of gabapentin, has been evaluated in a phase III clinical program for the treatment of restless legs syndrome, as well as completed a phase IIa clinical trial for the management of post-herpetic neuralgia; XP19986, a transported prodrug of R-baclofen for the treatment of gastroesophageal reflux disease and spasticity; and XP21279, a transported prodrug of levodopa, which is in phase I clinical trial for the treatment of Parkinson's disease. The company also develops XP21279, a transported prodrug of L-Dopa, for the treatment of Parkinson's disease; and XP21510, a transported prodrug of tranexamic acid, for the treatment of menorrhagia or heavy menstrual bleeding. XenoPort has strategic alliances with Astellas Pharma, Inc.; Glaxo Group Limited; and Xanodyne Pharmaceuticals, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.